In short
Pazopanib is an oral medication being studied in various clinical trials for its potential in treating different types of cancer. This article examines the use of pazopanib in clinical trials, focusing on its effectiveness, safety profile, and applications in conditions such as soft tissue sarcomas, renal cell carcinoma, and ovarian cancer. The trials aim to evaluate pazopanib's ability to inhibit tumor growth and improve patient outcomes.
At a glance
- Drug Name
- Pazopanib (also known as GW786034, Votrient)
- Mechanism of Action
- Inhibits multiple receptor tyrosine kinases, including VEGFR-1, VEGFR-2, and VEGFR-3
- Cancer Types Studied
- Advanced angiosarcoma, renal cell carcinoma, soft tissue sarcomas, ovarian cancer, neuroblastoma
- Administration
- Oral tablets or powder suspension, typically 400-800 mg daily
- Primary Outcomes Measured
- Progression-free survival, objective response rate, metabolic response rate
- Secondary Outcomes
- Overall survival, safety profile, pharmacokinetics, biomarker changes
- Imaging Techniques Used
- PET-CT, MRI, RECIST criteria
- Common Side Effects
- Changes in blood pressure, heart rate, liver function tests, blood cell counts
- Unique Applications
- Preoperative therapy in high-risk soft tissue sarcoma, combination with other drugs
- Patient Populations
- Adults with various solid tumors, including pediatric patients in some trials
What is Pazopanib?
Pazopanib is a medication used in the treatment of various types of cancer. It is also known by other names such as GW786034 and Votrient. Pazopanib belongs to a class of drugs called tyrosine kinase inhibitors, which work by targeting specific proteins involved in cancer growth.
How Pazopanib Works
Pazopanib works by inhibiting multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), platelet-derived growth factor receptors (PDGFA and B), and c-Kit. These receptors are involved in the process of angiogenesis (the formation of new blood vessels) and cancer progression. By blocking these receptors, pazopanib helps to:
- Reduce the blood supply to tumors, limiting their source of oxygen and nutrients
- Slow down or stop the growth of cancer cells
- Prevent the spread of cancer to other parts of the body
Conditions Treated with Pazopanib
Pazopanib has been studied and used in the treatment of various types of cancer, including:
- Soft Tissue Sarcoma: A type of cancer that develops in soft tissues such as muscles, tendons, and fat
- Renal Cell Carcinoma: A type of kidney cancer
- Advanced Angiosarcoma: A rare cancer that develops in the inner lining of blood vessels and lymph vessels
- Non-Small Cell Lung Cancer: A type of lung cancer that is less aggressive than small cell lung cancer
- Urothelial Carcinoma: A type of bladder cancer
How Pazopanib is Administered
Pazopanib is typically administered in the following ways:
- Oral tablets: The most common form of pazopanib is taken by mouth, usually at a dose of 800 mg once daily
- Eye drops: In some studies, pazopanib has been formulated as eye drops for conditions like macular degeneration
- Intravenous (IV) injection: In certain research settings, pazopanib has been administered through an IV for pharmacokinetic studies
The specific dosage and administration method may vary depending on the condition being treated and individual patient factors. It's important to take pazopanib exactly as prescribed by your healthcare provider.
Pazopanib in Clinical Trials
Pazopanib has been extensively studied in various clinical trials to evaluate its effectiveness and safety. Some notable trials include:
- A study comparing pazopanib to placebo in patients with soft tissue sarcoma
- A trial evaluating pazopanib in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma
- Research on pazopanib as an adjuvant therapy (additional treatment after surgery) for stage I non-small cell lung cancer
- A study comparing pazopanib plus TRC105 (another cancer drug) to pazopanib alone in patients with advanced angiosarcoma
These clinical trials help researchers understand how well pazopanib works for different types of cancer and in combination with other treatments.
Potential Side Effects
Like all medications, pazopanib can cause side effects. Some potential side effects observed in clinical trials include:
- Changes in blood pressure (both high and low)
- Alterations in heart rate
- Changes in blood cell counts (e.g., hemoglobin, white blood cells, platelets)
- Liver function changes
- Fatigue
- Nausea or vomiting
- Diarrhea
It's important to discuss potential side effects with your healthcare provider and report any unusual symptoms you experience while taking pazopanib.